The Expression And Regulation Of PCDH10 In Human Prostate Cancer Cell Lines

Objectives:To investigate the expression and regulation of PCDH10 in prostate cancer celllines.Methods: The expression and promoter methylation status of PCDH10 in four prostate cancercell lines (22RV1,PC3,DU145 and LNCaP) were analyzed by RT-PCR, real-time RT-PCR,Western Blotting, Immunofluorescence staining, methylation-specific PCR and bisulfatesequencing. The roles for DNA methylation and histone deacetylation on the expression ofPCDH10 were studied by the treatment of DNA methyltransferase inhibitor 5-azacytidine (AZA)and histone deacetylase inhibitor Trichostatin A (TSA) in prostate cancer cell lines.Results:PCDH10 mRNA was widely expressed in human tissues with a higher level in prostatetissue. The expression of PCDH10 was markedly reduced or silenced in prostate cancer cell linescompared with normal prostate tissue. PCDH10 expression was negatively correlated with themethylation status of PCDH10 promoter. Furthermore, after AZA treatment, PCDH10 promotermethylation was significantly decreased while mRNA level was obviously elevated in threeprostate cancer cell lines (22RV1,PC3 and LNCaP); However, the expression of PCDH10mRNA was enhanced only in LNCap cell line while there was no significant differences amongthe other cell lines after TSA treatment; When combined AZA and TSA, the overall effect of thiscomplex on PCDH10 mRNA was synergetic.Conclusion: The expression of PCDH10 was decreased in prostate cancer cell lines, which wasnegatively associated with the aberrant methylation in PCDH10 promoter. DNA methylation andhistone deacetylase were two crucial molecular events leading to lower expression of PCDH10in prostate cancer cell lines.